Literature DB >> 10836893

Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics.

.   

Abstract

This clinical practice guideline provides recommendations for the assessment and diagnosis of school-aged children with attention-deficit/hyperactivity disorder (ADHD). This guideline, the first of 2 sets of guidelines to provide recommendations on this condition, is intended for use by primary care clinicians working in primary care settings. The second set of guidelines will address the issue of treatment of children with ADHD. The Committee on Quality Improvement of the American Academy of Pediatrics selected a committee composed of pediatricians and other experts in the fields of neurology, psychology, child psychiatry, development, and education, as well as experts from epidemiology and pediatric practice. In addition, this panel consists of experts in education and family practice. The panel worked with Technical Resources International, Washington, DC, under the auspices of the Agency for Healthcare Research and Quality, to develop the evidence base of literature on this topic. The resulting evidence report was used to formulate recommendations for evaluation of the child with ADHD. Major issues contained within the guideline address child and family assessment; school assessment, including the use of various rating scales; and conditions seen frequently among children with ADHD. Information is also included on the use of current diagnostic coding strategies. The deliberations of the committee were informed by a systematic review of evidence about prevalence, coexisting conditions, and diagnostic tests. Committee decisions were made by consensus where definitive evidence was not available. The committee report underwent review by sections of the American Academy of Pediatrics and external organizations before approval by the Board of Directors. The guideline contains the following recommendations for diagnosis of ADHD: 1) in a child 6 to 12 years old who presents with inattention, hyperactivity, impulsivity, academic underachievement, or behavior problems, primary care clinicians should initiate an evaluation for ADHD; 2) the diagnosis of ADHD requires that a child meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria; 3) the assessment of ADHD requires evidence directly obtained from parents or caregivers regarding the core symptoms of ADHD in various settings, the age of onset, duration of symptoms, and degree of functional impairment; 4) the assessment of ADHD requires evidence directly obtained from the classroom teacher (or other school professional) regarding the core symptoms of ADHD, duration of symptoms, degree of functional impairment, and associated conditions; 5) evaluation of the child with ADHD should include assessment for associated (coexisting) conditions; and 6) other diagnostic tests are not routinely indicated to establish the diagnosis of ADHD but may be used for the assessment of other coexisting conditions (eg, learning disabilities and mental retardation). This clinical practice guideline is not intended as a sole source of guidance in the evaluation of children with ADHD. Rather, it is designed to assist primary care clinicians by providing a framework for diagnostic decisionmaking. It is not intended to replace clinical judgment or to establish a protocol for all children with this condition and may not provide the only appropriate approach to this problem.

Entities:  

Mesh:

Year:  2000        PMID: 10836893     DOI: 10.1542/peds.105.5.1158

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  188 in total

1.  Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do.

Authors:  Amelia M Arria; Robert L DuPont
Journal:  J Addict Dis       Date:  2010-10

2.  Variability in ADHD care in community-based pediatrics.

Authors:  Jeffery N Epstein; Kelly J Kelleher; Rebecca Baum; William B Brinkman; James Peugh; William Gardner; Phil Lichtenstein; Joshua Langberg
Journal:  Pediatrics       Date:  2014-11-03       Impact factor: 7.124

3.  The role of primary care physicians in attention-deficit/hyperactivity disorder.

Authors:  Laurel K Leslie
Journal:  Pediatr Ann       Date:  2002-08       Impact factor: 1.132

4.  Clonidine extended-release in attention-deficit hyperactivity disorder: profile report.

Authors:  Jamie D Croxtall
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

5.  Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010.

Authors:  Craig F Garfield; E Ray Dorsey; Shu Zhu; Haiden A Huskamp; Rena Conti; Stacie B Dusetzina; Ashley Higashi; James M Perrin; Rachel Kornfield; G Caleb Alexander
Journal:  Acad Pediatr       Date:  2012-02-10       Impact factor: 3.107

6.  Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha(2A)-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder.

Authors:  Martin P Cruz
Journal:  P T       Date:  2010-08

7.  Predicting the Early Developmental Course of Symptoms of Attention Deficit Hyperactivity Disorder.

Authors:  Camilla von Stauffenberg; Susan B Campbell
Journal:  J Appl Dev Psychol       Date:  2007-09

Review 8.  Assessment of attention in preschoolers.

Authors:  E M Mahone; H E Schneider
Journal:  Neuropsychol Rev       Date:  2012-10-23       Impact factor: 7.444

9.  The Investigation of Symptoms and Diagnoses of Adult-Attention Deficit/ Hyperactivity Disorder in Women with Iron Deficiency Anemia.

Authors:  Kadir Demirci; Funda Yildirim Baş; Bahriye Arslan; Zeliha Salman; Abdullah Akpinar; Arif Demirdaş
Journal:  Noro Psikiyatr Ars       Date:  2016-03-04       Impact factor: 1.339

10.  Predictors of diagnostic delay in a clinical sample of French children with attention-deficit/hyperactivity disorder.

Authors:  D Purper-Ouakil; S Cortese; M Wohl; M Asch; E Acquaviva; B Falissard; G Michel; P Gorwood; M C Mouren
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.